DRUG
Somapacitan
Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Status
Active, not recruiting
Phase
Phase 3
Enrollment
47
Locations
18
Results
Posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nurse will show how to inject somapacitan, so that the participant knows how to do it at home.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Feb 13, 2023
Study start
Feb 1, 2023
Primary completion
Jun 7, 2024
Study completion
Oct 29, 2027
Results posted
Nov 21, 2025
Registry updated
Jul 9, 2026
Outcomes
What the study measures.
Primary outcomes
Number of Adverse Events (AEs) Reported in Children Born Small for Gestational Age- Weeks 0 to 26
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs in children with short stature for indication SGA. Children with SGA are born small for gestational age with insufficient catch-up growth by 2 years of age or older. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported for Turner Syndrome (TS)- Weeks 0 to 26
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs in participants with short stature for indication TS. TS is a chromosomal disorder which leads to short stature. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported for Noonan Syndrome- Weeks 0 to 26
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs in participants with short stature for indication NS which is a genetically heterogeneous developmental disorder characterized by postnatally reduced growth and other major disorders. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported for Idiopathic Short Stature (ISS)- Weeks 0 to 26
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs in participants with short stature for indication ISS. ISS describes short children with normal GH secretion. ISS is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex and population, without evidence of systemic, endocrine, nutritional or chromosomal abnormalities. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Secondary outcomes
Number of Adverse Events Possibly or Probably Related to Somapacitan Reported for Children Born Small for Gestational Age
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs possibly or probably related to somapacitan reported in children with short stature for indication SGA. Children with SGA are born small for gestational age with insufficient catch-up growth by 2 years of age or older. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Possibly or Probably Related to Somapacitan Reported for Turner Syndrome
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs possibly or probably related to somapacitan reported in participants with short stature for indication TS. TS is a chromosomal disorder which leads to short stature. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Possibly or Probably Related to Somapacitan Reported for Noonan Syndrome
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs possibly or probably related to somapacitan reported in participants with short stature for indication NS. An NS is a genetically heterogeneous developmental disorder characterized by postnatally reduced growth and other major disorders. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Possibly or Probably Related to Somapacitan Reported for Idiopathic Short Stature
Time frame · From baseline (Week 0) to Week 26
This outcome measure reported number of AEs possibly or probably related to somapacitan in participants with short stature for indication ISS. ISS describes short children with normal GH secretion and it is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex and population, without evidence of systemic, endocrine, nutritional or chromosomal abnormalities. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported Long-term Safety for Children Born Small for Gestational Age- Weeks 0 to 156
Time frame · From baseline (Week 0) to Week 156
This outcome measure reported long-term safety in terms of number of AEs in children with short stature for indication SGA. Children with SGA are born small for gestational age with insufficient catch-up growth by 2 years of age or older. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported Long-term Safety for Turner Syndrome- Weeks 0 to 156
Time frame · From baseline (Week 0) to Week 156
This outcome measure reported long-term safety in terms of number of AEs in participants with short stature for indication TS. TS is a chromosomal disorder which leads to short stature. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported Long-term Safety for Noonan Syndrome- Weeks 0 to 156
Time frame · From baseline (Week 0) to Week 156
This outcome measure reported long-term safety in terms of number of AEs in participants with short stature for indication NS which is a genetically heterogeneous developmental disorder characterized by postnatally reduced growth and other major disorders. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Number of Adverse Events Reported Long-term Safety for Idiopathic Short Stature- Weeks 0 to 156
Time frame · From baseline (Week 0) to Week 156
This outcome measure reported long-term safety in terms of number of AEs in participants with short stature for indication ISS. ISS describes short children with normal GH secretion. ISS is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex and population, without evidence of systemic, endocrine, nutritional or chromosomal abnormalities. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an study treatment.
Height Velocity Reported Children Born Small for Gestational Age
Time frame · From Baseline (Week 0) to Week 26
This outcome measure reported height velocity in children with short stature for indication SGA. Height velocity at week 26 was derived as: (height at 26 weeks visit - height at baseline)/ (time from baseline to 26 weeks visit in years).
Height Velocity Reported for Turner Syndrome
Time frame · From Baseline (Week 0) to Week 26
This outcome measure reported height velocity in children with short stature for indication TS. Height velocity at week 26 was derived as: (height at 26 weeks visit - height at baseline)/ (time from baseline to 26 weeks visit in years).
Eligibility
Who can take part.
- Minimum age
- 10 Years
- Maximum age
- 18 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: Applicable to children with SGA: * Born small for gestational age (birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards). * Age: \- Male participants: Age equal to or above 11.0 years and below 18.0 years at screening. \- Female participants: Age equal to or above 10.0 years and below 18.0 years at screening. * Open epiphyses; defined as bone age less than (\<) 14 years for females and bone age \< 16 years for males. * For Growth Hormone (GH) treatment naïve participants: Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention. Applicable to children with TS: • Diagnosis of TS according to local clinical practice. * Age: \- Female participants: Age equal to or above 10.0 years and below 18.0 years at screening. * Open epiphyses; defined as bone age \< 14 years for females and bone age \< 16 years for males. * For GH treatment naïve participants: Impaired height defined as at least 2.0 standard deviation below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention. * For GH treatment naïve participants: Confirmed diagnosis of TS by 30-cell (or more) lymphocyte chromosomal analysis or confirmation of TS and TS mosaicism using comparative genomic hybridization (CGH)-array. Applicable to children with NS: * Diagnosis of NS according to local clinical practice. * Age: * Male participants: Age equal to or above 11.0 years and below 18.0 years at screening. * Female participants: Age equal to or above 10.0 years and below 18.0 years at screening. * Open epiphyses; defined as bone age \< 14 years for females and bone age \< 16 years for males. * For GH treatment naïve participants: Clinical diagnosis of NS according to van der Burgt score list and genetic test result or confirmed mutation in any of the genes associated with NS before allocation. Applicable to children with ISS: * Age: \- Male participants: Age equal to or above 11.0 years and below 18.0 years at screening. \- Female participants: Age equal to or above 10.0 years and below 18.0 years at screening. * Open epiphyses; defined as bone age \< 14 years for females and bone age \< 16 years for males. * For GH treatment naïve participants: Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening * For GH treatment naïve participants: Normal GH secretion (GH peak above 7 ng/mL) during GH stimulation test performed within 18 months prior to screening. * For GH treatment naïve participants: Bone age not delayed more than 2 years compared to chronological age at screening. Exclusion Criteria: * Children with suspected or confirmed growth hormone deficiency according to local practice. * Children diagnosed with diabetes mellitus or screening values from the central laboratory. * Fasting plasma glucose above or equal to 126 milligrams per deciliter (mg/dL) \[7.0 millimoles per litre (mmol/L)\] or * Glycated hemoglobin (HbA1c) above or equal to 6.5%. * Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening. * Children requiring inhaled glucocorticoid therapy at a dose greater than 400 micrograms per day (µg/day) of inhaled budesonide or equivalent (i.e., 250 µg/day for fluticasone propionate) for longer than 4 consecutive weeks within the last 12 months prior to screening. * History or known presence of malignancy including intracranial tumours. Applicable to children with SGA: • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with height, such as, but not limited to: * Poorly controlled or uncontrolled hormonal deficiencies. * Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal short stature homeobox (SHOX) gene analysis or absence of GH receptors. Applicable to children with TS: • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with height, such as, but not limited to: * Known family history of skeletal dysplasia. * Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants. * Any other disorder that can cause short stature such as, but not limited to nutritional disorders, chronic systemic illness and chronic renal disease. * Mosaicism below 10%. * TS with Y-chromosome mosaicism where gonadectomy has not been performed. * New York Heart Association (NYHA) class II or above or requiring medication for any heart condition. Applicable to children with NS: • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with height, such as, but not limited to: * Known family history of skeletal dysplasia. * Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants. * Any other disorder that can cause short stature such as, but not limited to nutritional disorders, chronic systemic illness and chronic renal disease. * Noonan-related disorders including but not limited to: Noonan syndrome with multiple lentigines (formerly called 'LEOPARD' syndrome), Noonan syndrome with loose anagen hair, cardiofaciocutaneous syndrome (CFC), Costello syndrome, neurofibromatosis type 1 (NF1) and Legius syndrome. Applicable to children with ISS: • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with height, such as, but not limited to: * Known family history of skeletal dysplasia. * Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants. * Any other disorder that can cause short stature such as, but not limited to nutritional disorders, chronic systemic illness and chronic renal disease. * Poorly controlled or uncontrolled hormonal deficiencies. * Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors.
Study locations
18 registered sites.
Malaysia · Netherlands · Poland · South Korea · Spain · United States. Showing up to 24 locations stored in the fast local snapshot.
Univ of AL at Birmingham_BRM
Birmingham, Alabama, United States
Sutter Valley Med Fdt Ped Endo
Sacramento, California, United States
Rocky Mt Ped and Endo
Centennial, Colorado, United States
Childrens National Medical Ctr
Washington D.C., District of Columbia, United States
Rocky Mt Clin Res, LLC
Idaho Falls, Idaho, United States
Children's Minnesota
Saint Paul, Minnesota, United States
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, Malaysia
University Technology MARA (UiTM) - Sg Buloh
Bandar Puncak Alam, Selangor, Malaysia
Erasmus MC
Rotterdam, Netherlands
Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie
Rzeszów, Podkarpackie Voivodeship, Poland
UCK, Klinika Pediatrii, Diabetologii i Endokrynologii,
Gdansk, Poland
Instytut Centrum Zdrowia Matki Polki
Lodz, Poland
Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie
Rzeszów, Poland
SPSK nr 1 im. prof.S.Szyszko w Zabrzu
Zabrze, Poland
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Asan Medical Center
Seoul, South Korea
Pusan National University Yangsan Hospital
Yangsan, South Korea
Hospital Vall d'Hebron
Barcelona, Spain
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Somapacitan.
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Novo Nordisk · SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3
Active, not recruiting
412
2026-06
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Novo Nordisk · Adult Growth Hormone Deficiency
Not applicable
Enrolling by invitation
400
2026-06
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
Novo Nordisk · Short Stature Children Born Small for Gestational Age (SGA)
Phase 2
Active, not recruiting
62
2026-06
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Novo Nordisk · Growth Hormone Deficiency in Children
Phase 3
Completed
200
2026-05
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
Novo Nordisk · Growth Hormone Deficiency in Children
Not applicable
Enrolling by invitation
200
2026-04
Growth Hormone for the Treatment of Gastroparesis
Mayo Clinic · Gastroparesis
Early Phase 1
Recruiting
10
2026-04
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
Novo Nordisk · Adult Growth Hormone Deficiency
Not applicable
Active, not recruiting
200
2026-04
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
Novo Nordisk · Growth Hormone Deficiency · Neoplasms
Not applicable
Enrolling by invitation
500
2026-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.